Scynexis (SCYX) Net Shares Issued and Repurchased (2021 - 2026)
Scynexis' (SCYX) quarterly Net Shares Issued and Repurchased came in at $30204.0 in Q1 2026, down 95.5% on a YoY basis from $671925.0 in Q1 2025, and down 96.27% quarter-over-quarter from $809925.0 in Q4 2025.
Analysis
Scynexis (SCYX) Net Shares Issued and Repurchased (2021 - 2026) Analysis & Trends
Scynexis (SCYX) has reported Net Shares Issued and Repurchased for 6 consecutive years, with $30204.0 the latest figure, recorded in Q1 2026.
- For the quarter ending Q1 2026, Net Shares Issued and Repurchased fell 95.5% year-over-year to $30204.0; the trailing twelve-month figure through Mar 2026 stood at $30204.0 (down 95.5% YoY), and the FY2025 full-year result was $809925.0, down 24.31% from the prior year.
- Net Shares Issued and Repurchased eased to $30204.0 in Q1 2026 per SCYX's latest filing, from $809925.0 in the prior quarter.
- Across five years, Net Shares Issued and Repurchased topped out at $1.1 million in Q4 2024 and bottomed at $30204.0 in Q1 2026.
- Historically, Net Shares Issued and Repurchased has averaged $541686.0 across 5 years, with a median of $671925.0 in 2025.
- The sharpest annual moves came in 2022 and 2026: Net Shares Issued and Repurchased jumped 344.09% in 2022, then tumbled 95.5% in 2026.
- Over 5 years, Net Shares Issued and Repurchased stood at $834000.0 in 2022, then slumped by 63.67% to $303000.0 in 2023, then soared by 253.16% to $1.1 million in 2024, then fell by 24.31% to $809925.0 in 2025, then tumbled by 96.27% to $30204.0 in 2026.
- According to Business Quant data, Net Shares Issued and Repurchased over the past three periods registered $30204.0, $809925.0, and $671925.0 for Q1 2026, Q4 2025, and Q1 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Shares Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 30,204.00 |
| Dec 31, 2025 | 809,925.00 |
| Mar 31, 2025 | 671,925.00 |
| Dec 31, 2024 | 1.07 Mn |
| Mar 31, 2024 | 862,060.00 |
| Dec 31, 2023 | 303,000.00 |
| Mar 31, 2023 | 225,000.00 |
| Dec 31, 2022 | 834,000.00 |
| Mar 31, 2022 | 69,000.00 |
| Dec 31, 2021 | 187,800.00 |